Current Hematologic Malignancy Reports

, Volume 7, Issue 3, pp 216–220 | Cite as

The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

Lymphomas (J Armitage and P McLaughlin, Section Editors)

Abstract

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton’s tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

Keywords

Non-Hodgkin lymphoma B cell receptor Targeted therapy Spleen tyrosine kinase (Syk) Bruton’s tyrosine kinase (BTK) phosphoinositide 3-kinase (PI3K) 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787–800.PubMedCrossRefGoogle Scholar
  2. 2.
    Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.PubMedCrossRefGoogle Scholar
  4. 4.
    Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715–9.PubMedGoogle Scholar
  5. 5.
    Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108:3135–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.PubMedCrossRefGoogle Scholar
  10. 10.
    • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-85. This is the first publication revealing the promise of BCR targeting in B cell lymphomas. Google Scholar
  11. 11.
    Satterthwaite AB, Witte O. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Advani A, Sharman J, Smith SM. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. Ann Oncol. 2011;22 (Suppl 4).Google Scholar
  15. 15.
    Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.PubMedCrossRefGoogle Scholar
  16. 16.
    •• O'Brien S Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow up of a phase IB/II study. Blood. 2011; 118: Abstract 983. This abstract details the phase II experience with PCI 32765 in CLL. Google Scholar
  17. 17.
    •• Wang L, Martin P, Blum KA, et al. The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood. 2011;118: Abstract 442. This abstract details the phase II experience with PCI 32765 in MCL. Google Scholar
  18. 18.
    Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–4.PubMedCrossRefGoogle Scholar
  19. 19.
    • Furman RR, Byrd JC, Brown JR et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 2010; 116: Abstract 55. This abstract details the phase I experience with CAL 101 in CLL. Google Scholar
  20. 20.
    • Kahl BS, Byrd JC, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 2010; 116: Abstract 1777. This abstract details the phase I experience with CAL 101 in NHL. Google Scholar
  21. 21.
    De Vos S, MT S, IW F. A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 2011;118:Abstract 2699.Google Scholar
  22. 22.
    Sharman J, de Vos S, Leonard JP. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood 2011;118:Abstract 1787.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.University of WisconsinMadisonUSA
  2. 2.University of WisconsinMadisonUSA
  3. 3.Department of Medicine, Division of Hematology/OncologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  4. 4.UW Carbone Cancer CenterMadisonUSA

Personalised recommendations